These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 34725056)

  • 1. Impact of medical therapies for inflammatory bowel disease on the severity of COVID-19: a systematic review and meta-analysis.
    Alrashed F; Battat R; Abdullah I; Charabaty A; Shehab M
    BMJ Open Gastroenterol; 2021 Oct; 8(1):. PubMed ID: 34725056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of biologics and small molecules for inflammatory bowel disease on COVID-19-related hospitalization and mortality: A systematic review and meta-analysis.
    Alrashed F; Alasfour H; Shehab M
    JGH Open; 2022 Apr; 6(4):241-250. PubMed ID: 35475207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COVID-19 and Outcomes in Patients With Inflammatory Bowel Disease: Systematic Review and Meta-Analysis.
    Tripathi K; Godoy Brewer G; Thu Nguyen M; Singh Y; Saleh Ismail M; Sauk JS; Parian AM; Limketkai BN
    Inflamm Bowel Dis; 2022 Aug; 28(8):1265-1279. PubMed ID: 34718595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of severe COVID-19 in patients treated with IBD medications: a French nationwide study.
    Meyer A; Semenzato L; Zureik M; Weill A; Carbonnel F; Dray-Spira R
    Aliment Pharmacol Ther; 2021 Jul; 54(2):160-166. PubMed ID: 34110040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.
    Singh S; Facciorusso A; Dulai PS; Jairath V; Sandborn WJ
    Clin Gastroenterol Hepatol; 2020 Jan; 18(1):69-81.e3. PubMed ID: 30876964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of adverse outcomes in inflammatory bowel disease patients infected with SARS-CoV-2: a systematic review and meta-analysis.
    Chen L; Hu K; Cheng C; Hu Q; Zhang L; An T; Guo Y; Chen S; Duan G
    Int J Colorectal Dis; 2022 Nov; 37(11):2277-2289. PubMed ID: 36271206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry.
    Brenner EJ; Ungaro RC; Gearry RB; Kaplan GG; Kissous-Hunt M; Lewis JD; Ng SC; Rahier JF; Reinisch W; Ruemmele FM; Steinwurz F; Underwood FE; Zhang X; Colombel JF; Kappelman MD
    Gastroenterology; 2020 Aug; 159(2):481-491.e3. PubMed ID: 32425234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of biologics in inflammatory bowel disease patients with COVID-19.
    Weissman S; Aziz M; Smith WL; Elias S; Swaminath A; Feuerstein JD
    Int J Colorectal Dis; 2021 Sep; 36(9):2051-2055. PubMed ID: 34131784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of SARS-CoV-2 vaccination in inflammatory bowel disease patients with different biological agents: a systematic review and meta-analysis.
    Dai C; Dong ZY; Wang YN; Huang YH; Jiang M
    Rev Esp Enferm Dig; 2023 Jun; 115(6):306-314. PubMed ID: 36353949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19 susceptibility and clinical outcomes in inflammatory bowel disease: An updated systematic review and meta-analysis.
    Lee MH; Li HJ; Wasuwanich P; Kim SE; Kim JY; Jeong GH; Park S; Yang JW; Kim MS; Yon DK; Lee SW; Koyanagi A; Jacob L; Kim EY; Cheon JH; Shin JI; Smith L
    Rev Med Virol; 2023 Mar; 33(2):e2414. PubMed ID: 36504172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. No Benefit of Concomitant Immunomodulator Therapy on Efficacy of Biologics That Are Not Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases: A Meta-analysis.
    Yzet C; Diouf M; Singh S; Brazier F; Turpin J; Nguyen-Khac E; Meynier J; Fumery M
    Clin Gastroenterol Hepatol; 2021 Apr; 19(4):668-679.e8. PubMed ID: 32629124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of COVID-19 in Patients with Inflammatory Bowel Disease: Comparison with Household Members and the Role of IBD Medications.
    Sima AR; Saberzadeh-Ardestani B; Vahedi H; Fakheri H; Mansour-Ghanaei F; Maleki I; Nasseri-Moghaddam S; Vosoghinia H; Ghadir MR; Hormati A; Kasaeian A; Radmard AR; Khosravi B; Malekzadeh M; Alatab S; Sadeghi A; Aminisani N; Poustchi H; Gonoudi E; Anushiravani A; Rayatpisheh M; Colombel JF; Ungaro RC; Malekzadeh R
    Arch Iran Med; 2022 Jan; 25(1):17-25. PubMed ID: 35128908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study.
    Bezzio C; Armuzzi A; Furfaro F; Ardizzone S; Milla M; Carparelli S; Orlando A; Caprioli FA; Castiglione F; Viganò C; Ribaldone DG; Zingone F; Monterubbianesi R; Imperatore N; Festa S; Daperno M; Scucchi L; Ferronato A; Pastorelli L; Balestrieri P; Ricci C; Cappello M; Felice C; Fiorino G; Saibeni S;
    Aliment Pharmacol Ther; 2021 Dec; 54(11-12):1432-1441. PubMed ID: 34694009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for SARS-CoV-2 infection and course of COVID-19 disease in patients with IBD in the Veterans Affair Healthcare System.
    Khan N; Mahmud N; Trivedi C; Reinisch W; Lewis JD
    Gut; 2021 Sep; 70(9):1657-1664. PubMed ID: 33753416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expert Opinions on the Current Therapeutic Management of Inflammatory Bowel Disease during the COVID-19 Pandemic: Japan IBD COVID-19 Taskforce, Intractable Diseases, the Health and Labor Sciences Research.
    Nakase H; Matsumoto T; Matsuura M; Iijima H; Matsuoka K; Ohmiya N; Ishihara S; Hirai F; Wagatsuma K; Yokoyama Y; Hisamatsu T
    Digestion; 2021; 102(5):814-822. PubMed ID: 32892197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Corticosteroids but not Anti-TNF Are Associated With Increased COVID-19 Complications in Patients With Inflammatory Bowel Disease.
    Long MD; Parlett L; Lewis JD; Haynes K; Adimadhyam S; Hou L; Wolfe A; Toh S; Burris J; Dorand J; Kappelman MD
    Inflamm Bowel Dis; 2024 Aug; 30(8):1345-1352. PubMed ID: 37611117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of Postoperative Infectious Complications From Medical Therapies in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
    Law CCY; Koh D; Bao Y; Jairath V; Narula N
    Inflamm Bowel Dis; 2020 Nov; 26(12):1796-1807. PubMed ID: 32047894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thiopurine therapy in inflammatory bowel disease in the pandemic era: Safe or unsafe?
    Perdalkar S; Basthi Mohan P; Musunuri B; Rajpurohit S; Shetty S; Bhat K; Pai CG
    Int Immunopharmacol; 2023 Mar; 116():109597. PubMed ID: 36702073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review Article: vaccination for patients with inflammatory bowel disease during the COVID-19 pandemic.
    Doherty J; Fennessy S; Stack R; O' Morain N; Cullen G; Ryan EJ; De Gascun C; Doherty GA
    Aliment Pharmacol Ther; 2021 Nov; 54(9):1110-1123. PubMed ID: 34472643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of patients with Intestinal Bowel Disease and COVID-19: A review of current evidence and future perspectives.
    Suria C; Bosca-Watts MM; Navarro P; Tosca J; Anton R; Sanahuja A; Revaliente M; Minguez M
    Gastroenterol Hepatol; 2022 May; 45(5):383-389. PubMed ID: 34171421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.